Berlin - Delayed Quote EUR

Ocugen Inc (2H51.BE)

Comparar
0.7285
+0.0280
+(4.00%)
A partir del 8:01:01 AM GMT+1. Mercado abierto.
Todos Todos Favoritos Texto Estadísticas Datos técnicos Fibonacci Marcas Líneas
Cargando gráfico de 2H51.BE

Noticias recientes: 2H51.BE

Más detalles
Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19
GlobeNewswire 3 days ago
Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment

Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment
Clinical Trials Arena 13 days ago
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
GlobeNewswire 14 days ago
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa
GlobeNewswire 17 days ago
5 Biotech Breakthrough Stocks to Watch in 2025

5 Biotech Breakthrough Stocks to Watch in 2025
Zacks last month
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
GlobeNewswire last month
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
GlobeNewswire last month
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
GlobeNewswire 2 months ago
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
GlobeNewswire 2 months ago
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
GlobeNewswire 2 months ago
Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates

Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates
Zacks 2 months ago
Más detalles

Pizarras relacionadas

0OT.F Ocular Therapeutix, Inc.
7.41
-0.96%
 
VLA.VI Valneva SE
2.7960
+16.79%
 
0K4.F Akero Therapeutics, Inc.
54.08
+4.77%
 
IVVD Invivyd, Inc.
0.3900
+1.22%
 
GOVX GeoVax Labs, Inc.
1.9500
+3.72%
 
SGMO Sangamo Therapeutics, Inc.
1.2300
+8.85%
 
NVAX Novavax, Inc.
9.01
+2.27%
 
PPCB Propanc Biopharma, Inc.
25.00
0.00%
 
RXRX Recursion Pharmaceuticals, Inc.
7.69
+7.40%
 
AKRO Akero Therapeutics, Inc.
55.36
+2.52%